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Autosomal recessive polycystic kidney disease (ARPKD) is a severe monogenic disorder that occurs due to mutations in the
PKHD1 gene. Congenital hepatic fibrosis (CHF) associated with ARPKD is characterized by the presence of hepatic cysts derived
from dilated bile ducts and a robust, pericystic fibrosis. Cyst growth, due to cyst wall epithelial cell hyperproliferation and fluid
secretion, is thought to be the driving force behind disease progression. Liver fibrosis is a wound healing response in which
collagen accumulates in the liver due to an imbalance between extracellular matrix synthesis and degradation. Whereas both
hyperproliferation and pericystic fibrosis are hallmarks of CHF/ARPKD, whether or not these two processes influence one another
remains unclear. Additionally, recent studies demonstrate that inflammation is a common feature of CHF/ARPKD. Therefore, we
propose a “pathogenic triumvirate” consisting of hyperproliferation of cyst wall growth, pericystic fibrosis, and inflammationwhich
drives CHF/ARPKD progression. This review will summarize what is known regarding the mechanisms of cyst growth, fibrosis,
and inflammation in CHF/ARPKD. Further, we will discuss the potential advantage of identifying a core pathogenic feature in
CHF/ARPKD to aid in the development of novel therapeutic approaches. If a core pathogenic feature does not exist, then developing
multimodality therapeutic approaches to target each member of the “pathogenic triumvirate” individually may be a better strategy
to manage this debilitating disease.
1. Introduction
Autosomal recessive polycystic kidney disease (ARPKD) is
a rare genetic disorder that occurs in 1 : 20,000 live births. It
develops in utero and is mainly diagnosed in pregnancy or in
the immediate neonatal period. Among all affected patients,
approximately 30% die shortly after birth, primarily of pul-
monary insufficiency [1]. Patients who survive the neonatal
period present with a broad spectrum of symptoms involving
the kidneys, liver, and pancreas. Renal manifestations are
characterized by the presence of cysts that are derived from
dilated collecting ducts and distal tubules [2, 3]. A significant
portion of patients will progress to end stage renal disease
either during the first decade or during adolescence [4].
A minority of patients develop pancreatic abnormalities
consisting of cysts and fibrosis [5, 6]. All patients with
ARPKD develop some degree of congenital hepatic fibrosis
(CHF), which, as the name would suggest, is present at
birth. CHF is characterized by bile duct dilation resulting in
eventual development of cysts and pericystic fibrosis in the
liver [7, 8]. Accompanying cyst growth and fibrosis, recent
reports suggest that inflammation is also present and likely
contributes to disease pathogenesis and/or progression [9–
12]. Aside from management of symptoms and liver and/or
kidney transplant, no effective pharmacologic therapies exist
for CHF/ARPKD [13].
Although CHF is most commonly thought to be asso-
ciated with ARPKD, there are several cases reported in
autosomal dominant polycystic kidney disease (ADPKD).
The patients with ADPKD showed hepatic cysts and fibrosis
at birth, which is consistent with symptoms described in
CHF/ARPKD [14]. Other ciliopathies in which CHF is
found include Meckel-Gruber syndrome [15], renal-hepatic-
pancreatic dysplasia (an autosomal recessive disorder with
renal dysplasia and pancreatic fibrosis) [16], and COACH
syndrome (a subset of Joubert Syndrome Related Disorders,
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Table 1: Current rodent models of ARPKD.
Model Species Liver phenotype Kidney phenotype Other phenotypes Reference
PCK Rat Cysts and fibrosis Cysts Pancreatic cysts [29]
BALB/c-cpk/cpk Mouse Cysts and fibrosis Cysts Pancreatic cysts and fibrosis [33]
C57BL/6J-cpk/cpk Mouse No liver disease Cysts None [34]
Pkhd1del2/del2 Mouse Cysts and fibrosis Cysts in female Pancreatic cysts [35]
Pkhd1LSL(−)/LSL(−) Mouse Cysts and fibrosis Cysts in female Unknown [36]
Pkhd1exon40 Mouse Cysts and fibrosis No kidney disease Portal hypertension [37]
Pkhd1lacZ/lacZ Mouse Cysts and fibrosis Cysts Pancreatic and gall bladder cysts [5]
Pkhd1del4/del4 Mouse Cysts and fibrosis No kidney disease Pancreatic cysts, splenomegaly [38]
an autosomal recessive multisystemic disorder with cerebel-
lar vermis hyperplasia, ataxia, and mental retardation) [17].
2. Gene Defects in ARPKD
CHF/ARPKD is caused by mutations in the PKHD1 gene.
PKHD1 extends over 470 kb, includes a minimum of 86
exons, and encodes a 4,074-amino-acid protein called fibro-
cystin/polyductin. Fibrocystin is predicted to be a receptor-
like protein that consists of a large glycosylated extracellular
region, a single transmembrane domain, and a short cytoplas-
mic tail [18, 19]. Fibrocystin is expressed in the primary cilia
of epithelial cells. Immunohistochemistry studies suggest that
fibrocystin is located in renal collecting ducts and loops of
Henle, pancreatic epithelial ducts, and hepatic biliary ducts
[20]. Different mutations in PKHD1 have been described
in human ARPKD patients, including missense mutations,
deletion/insertionmutations, and splicingmutations. Among
all types of mutations found in PKHD1, about 45% of them
are predicted to truncate fibrocystin [21]. Disease in patients
carrying two truncating mutations is usually more severe,
whereas patients bearingmissensemutations exhibit amilder
phenotype [22].
3. Current Therapies for ARPKD
There is currently no pharmacologic cure for CHF/ARPKD.
Treatment mainly focuses on management of symptoms
and includes therapies for cardiac hypertension, chronic
liver/kidney disease, cholangitis, and portal hypertension
[23]. Hypertension associated with chronic kidney disease
occurs at the early stage of disease and is regulated by
the renin-angiotensin system (RAS) [24]. Hypertension
in ARPKD is treated empirically. Angiotensin converting
enzyme (ACE) inhibitors and angiotensin II receptor block-
ers (ARBs) are considered the main treatment options in
ARPKD patients [8, 25]. If kidney failure occurs, patients
undergo dialysis or kidney transplantation. CHF/ARPKD
can be accompanied by recurrent cholangitis and cholangio-
carcinoma. Although the occurrence of recurrent cholangitis
and cholangiocarcinoma is relatively rare, liver transplan-
tation is indicated to decrease mortality [26, 27]. Other
therapeutic strategies include targeting components of the
cAMP signaling pathway since cAMP levels are increased
in cyst wall epithelial cells (CWECs) and drive CWEC
proliferation. Octreotide and pasireotide, two somatostatin
analogs, decrease proliferation of PCK rat CWEC in vitro
and inhibit hepatorenal cyst growth in PCK rats in vivo by
reducing cAMP levels. Consistently, clinical trials in patients
with polycystic liver disease (PLD) and ADPKD showed that
octreotide or lanreotide is well tolerated and decreases total
liver volume by 4%–6% [13].
4. Animal Models of ARPKD
A number of rodent models of human ARPKD exist to
study the mechanisms of disease and to test therapeutic
strategies (Table 1). One of the best-characterized models
is the polycystic kidney (PCK) rat, derived from Sprague-
Dawley (SD) rats at Charles River, Inc. [28]. The PCK rat
carries a spontaneous splicingmutation, IVS35-2A→T, in the
rat Pkhd1 gene [19]. PCK rats bear hepatic and renal cysts
and associated fibrosis, similar to human ARPKD [29]. The
lifespan of a PCK rats is about 1.5 years, and they develop
numerous cysts in kidneys and liver by one year of age [30].
Inmice, the congenital polycystic kidney (cpk)mousemimics
humanARPKD.Thismouse harbors a spontaneousmutation
in cpk gene, the gene that encodes a 145-amino-acid protein
termed cystin. Cystin is mainly located in the axoneme of
the primary cilia found in the kidney proximal tubules and
collecting ducts and in the cholangiocytes found in the liver
[31, 32]. cpk mice, on the BALB/c background, exhibit both
renal and extrarenal manifestations associated with cystin
mutations [33]. When on a C57Bl/6J background, cpk mice
do not have extrarenal pathology [34], limiting the utility of
this model for those interested in studying CHF/ARPKD. In
addition, 𝑃𝑘ℎ𝑑1del2/del2 mouse model, which lacks exon 2 of
the mouse Pkhd1 gene, also reproduces the human ARPKD
pathology. Femalemice develop dilation of the renal proximal
tubule and cysts by 3 months of age, whereas male mice
are protected from renal cysts. Both genders develop hepatic
cysts and fibrosis by 3 months as a result of biliary ductal
plate malformation [35]. Another widely accepted murine
model with Pkhd1 mutation was generated by Christopher
Ward and colleagues. In this model, the Pkhd1 gene was
transcriptionally silenced by inserting a loxP flanked STOP
(LSL) cassette into intron-2. 𝑃𝑘ℎ𝑑1LSL(−)/LSL(−) mice, both
male and female, develop liver cysts and fibrosis at 3 months
of age [36]. In addition, by disrupting exon 40, homozygous
Pkhd1mutantmice exhibit severe hepatic cysts and pericystic
fibrosis in neonates due to biliary malformation in the
embryo. However, the morphology and function in kidneys
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are not affected [37]. Another well-described murine model
is the homozygous 𝑃𝑘ℎ𝑑1𝑙𝑎𝑐𝑍/𝑙𝑎𝑐𝑍 mice. They are widely
accepted as an ARPKD mouse model due to the presence
of both hepatic and renal manifestations [5]. 𝑃𝑘ℎ𝑑1𝑑𝑒𝑙4/𝑑𝑒𝑙4
mouse is described predominantly as a model for CHF, since
the kidneys are unaffected by the mutation [38]. Among all
rodent models for ARPKD, the PCK rat is one of the few
commercially available models to date, and the phenotypic
resemblance to human ARPKD makes it an incredibly valu-
able resource for CHF/ARPKD researchers.
5. Mechanisms of Cystogenesis in ARPKD
Although the mechanisms of cystogenesis are not well char-
acterized in human ARPKD, a study using PCK rats sug-
gested a possible link between cystogenesis and ciliary dys-
function [39]. Primary cilia, microtubule-based organelles,
extend from the surface of eukaryotic cells. Primary cilia are
nonmotile cilia containing a “9+0” axoneme, and function
as mechano-, osmo-, and chemosensors that deliver signals
from the extracellular environment into the cell [40]. The
abnormal primary cilia in PCK rat cholangiocytes may
compromise their sensory organelle function in response to
fluid secretion or fluid flow. Recent research suggests that
primary cilia are also important components of multiple
signaling pathways such as the hedgehog and PDGF-A
signaling pathways [41, 42].
Hepatic cyst development in human ARPKD patient is
characterized by abnormal remodeling of ductal plate from
the double cell layer. Clinical manifestations include dilated
bile ducts, an increased number of bile ducts, and abnormal
branching [8]. Whether the hepatic cysts are disconnected
from the biliary as they grow remains to be studied although
it is the case in ADPKD patients [43]. Cyst development in
PCK rat liver has been well-described by Dr. La Russo’s group
[13, 44, 45]. They found that (1) hepatic cysts are derived
from bile duct segments due to ductal plate malformation
during development and (2) most cysts become isolated
from biliary tree by 6 months of age [39]. Along with cyst
formation, the mechanisms of cyst expansion are proposed
to be the result of the following: (1) cholangiocyte hyperpro-
liferation, (2) cell-matrix interactions, and (3) fluid secretion
[46]. Many factors can regulate these processes through
different signaling pathways and are briefly described
below.
(1) Intracellular cyclic adenosine monophosphate
(cAMP) is likely the major driver of hepatic cyst growth [13].
In addition, cAMP levels are elevated in PCK rat cholangio-
cytes as compared to cholangiocytes from control, SD rats.
Octreotide, a somatostatin analog, reduces hepatic and renal
cyst expansion in PCK rats by decreasing cAMP levels [47].
Another factor that contributes to CWEC proliferation is low
intracellular [Ca2+], which is reduced in CWECs from PCK
rat livers [48]. Activation of Trpv4, a calcium-permeable
cation channel expressed in normal cholangiocytes, increases
intracellular calcium levels and suppresses proliferation of
cholangiocytes isolated fromPCK rats in vitro [46]. Although
the mechanisms of cyst growth have been well-described,
whether targeting cAMP or intracellular [Ca2+] will prevent
disease progression in humans is inconsistent [13]. (2)
Remodeling of extracellular matrix includes alteration of
extracellular matrix composition, basement membrane
thickness, and the activities of matrix metalloproteases
(MMPs) and their inhibitors, all of which can lead to cyst
expansion [49]. (3) In ARPKD, little is known about how
fluid secretion impacts hepatic cyst expansion. Previous
data suggest that cystic epithelia can respond to secretin and
secrete fluid through activating cAMP-dependent signaling
pathway [50, 51].
In contrast to the origin of cyst development in liver, renal
cysts inARPKDare commonly described as dilated collecting
ducts [52]. In contrast to what is observed in ADPKD,
dilated collecting ducts and distal tubules lined with cuboidal
or columnar epithelia remain connected to the urinary
system [53]. It remains unclear in ARPKD whether or not
cysts with squamous epithelia cells detach from the tubular
segment from which they are derived [54]. Cyst formation
and expansion are associated with increased proliferation of
renal epithelial cells [55] and altered fluid secretion [56].
Recent data suggest that cAMP induces renal epithelial cell
proliferation and promotes cyst growth by activating PKA/B-
Raf/MAPK pathways in CWECs from ARPKD patients [57].
Similarly, renal epithelial cells also exhibit a lower level of
intracellular [Ca2+] and sustained reduction of intracellular
[Ca2+] in normal cells induces a cAMP-growth stimulated
phenotype [57]. In addition, an increased level of epidermal
growth factor (EGF) receptor is demonstrated in renal cyst
fluid, which is consistent with an overexpression of EGF
receptor (EGFR) mRNA and protein in renal epithelia in
cpk mice [58]. The administration of EGFR tyrosine kinase
inhibitor does not protect PCK rats from developing renal
cysts, possibly due to an increased level of cAMP after
treatment [59].
6. Mechanisms of Fibrosis in ARPKD
Liver fibrosis results from chronic liver injury in conjunction
with the accumulation of extracellularmatrix (ECM)proteins
synthesized by myofibroblasts (MFB). In the liver, the major
cell types that contribute to MFB formation are hepatic
stellate cells (HSCs) and portal fibroblasts (PFs). Residing
in the space of Disse, HSCs are the principal cell type
responsible for collagen synthesis in response to liver injury
or changes in ECM stiffness [60]. HSCs are also activated
by various mediators released from Kupffer cells, the liver-
resident macrophage population, and include transforming
growth factor-beta (TGF-𝛽) and tumor necrosis factor-alpha
(TNF-𝛼) [61]. In addition, produced by multiple cells types
in liver, connective tissue growth factor (CTGF) promotes
the activation of HSCs [62]. When HSCs are activated, they
convert from quiescent cells into proliferative, fibrogenic,
and contractile MFB and release a variety of inflamma-
tory chemoattractants such as monocyte chemoattractant
protein-1 (MCP-1) to recruit monocytes to the liver [63].
PFs are found in the portal tract area and play a pre-
dominant role in biliary fibrosis [64]. Although both cell
types express alpha smooth muscle actin (𝛼SMA) upon
activation, research suggests that the MFB population that
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contributes to CHF/ARPKD is likely derived from PFs [65].
Similar to HSCs, TGF-𝛽 and CTGF are involved in the
activation of PFs [66–68]. By contrast, TNF-𝛼 does not seem
important for PF activation or fibrogenic potential [64]. In
addition to their role in biliary fibrosis, activated portal
MFB regulate cholangiocyte proliferation through activating
P2Y receptors on bile duct epithelia [69]. Following the
activation of HSCs or PFs to MFB, two major events occur
which promote fibrogenesis. First, activated MFB directly
increase the synthesis and deposition of ECM proteins.
Second, theMFB proliferate and amplify the fibrotic response
[70].
Matrix degradation is an importantmechanism to reverse
fibrosis or cirrhosis and can restore normal liver architec-
ture. Two kinds of matrix degradation mechanisms exist:
“pathologic matrix degradation” that disrupts low density
matrix and “restorative matrix degradation” that degrades
excess scar [71]. Matrix remodeling is carried out through a
fine balance between activities of MMPs and their inhibitors.
MMPs are a family of enzymes secreted as proenzymes and
are activated by proteolytic cleavage. They play a pivotal
role in the regression of liver fibrosis by degrading ECM
and inducing MFB apoptosis. Expression of tissue inhibitors
of metalloproteinase 1 (TIMP-1) promotes fibrosis, first, by
inhibiting MMP activity, and, second, by inhibiting MFB
apoptosis [72].
The connection between cyst growth and fibrosis in
CHF/ARPKD is thus far unclear. Cystogenesismay be the ini-
tial event that disrupts normal ECM remodeling and induces
fibrogenesis. This hypothesis is supported by the fact that
HSCs and PFs are activated and differentiate into MFB when
microenvironmental stiffness increases [66, 73]; enlarging
cysts may promote this increase in mechanical stiffness and
facilitate PF and HSC activation. Recent evidence suggests
that bile duct epithelia directly regulate PF proliferation
and PF transdifferentiation to MFB via release of MCP-1
[74]. These data indicate that release of MCP-1 is likely an
additional link between cyst growth and fibrosis.
Compared to what has been established regarding devel-
opment of hepatic fibrosis, little is known about renal fibrosis
regarding the mechanisms and consequences in ARPKD.
Although the patients exhibit very different renal symptoms,
they always develop some degree of interstitial fibrosis
accompanied with renal cysts [75]. In PCK rats, the renal
interstitial fibrosis is not evident until 70 days of age, and the
renal disease is more severe in males than in females [29].
7. Mechanisms of Inflammation in ARPKD
In addition to cyst growth and fibrosis, inflammation is
another pathological feature of CHF/ARPKD. Although
inflammation in the liver has not been well studied as that
in the kidney, immune cells such as mast cells (MC) are
found accumulated in the pericystic areas in livers of human
CHF/ARPKD patients [76]. Consistently, we have observed
pericystic MC infiltration in PCK rats (data not shown).
Inhibition of MC degranulation and histamine release with
cromolyn sodium, a MC stabilizer, decreases cholangio-
cyte proliferation in bile duct ligation-induced cholestasis
[77], suggesting MC may also contribute to cholangiocyte-
derived, CWEC proliferation. Moreover, upregulation of
genes involved in innate immune responses, including acti-
vated complement protein 3 (C3a) and theMCP-1 receptor, is
detected in cpkmice [78]. Taken together, these data suggest
that activation of innate immune effector cells and associated
proteins contributes to progression of PKD in general as well
as in CHF/ARPKD.
Although PKD is not primarily considered an inflamma-
tory disorder, accumulating evidence suggests that inflamma-
tion occurs in the early stage of the disease andmay also drive
disease progression. For example, macrophage infiltration is
found in the renal interstitium in human ADPKD patients
with kidney failure [79]. Activated macrophages stimulate
vascular endothelial cell proliferation in vitro [80]. Further,
TNF-𝛼, an inflammatory cytokine, is present in renal cyst
fluid of human ADPKD and induces renal cyst formation
through regulating polycystin-2 [81]. In ARPKD, M2-like
macrophages are present in kidneys of patients and in cpk
mice [82], supporting a role of macrophages in the progres-
sion of ARPKD.Work fromothers has found increasedMCP-
1 in kidneys [83] from PCK rats. Consistent with a role for
MCP-1 and macrophage infiltration in progression in PKD,
inhibition of MCP-1 synthesis with bindarit reduces renal
inflammation and renal dysfunction but did not attenuate
cyst growth [83]. Whether or not MCP-1 depletion affected
hepatic inflammation, cyst growth, or fibrosis was not evalu-
ated in this study.
We characterized hepatic cyst development in PCK rats
by calculating liver/body weight ratio (%) and quantifying
cyst number, compared to SD rats frompostnatal days (PND)
0 to 90 (Figure 1). Consistent with the work of others [29], our
data suggest that PCK rats had increased liver/body weight
ratios (Figure 1(a)) which was paralleled by an increase in
the number of cysts from PND 10 onward (Figure 1(b)).
Consistently, a positive correlation exists between liverweight
and cyst number, further supporting a relationship between
these disease-related parameters (Figure 1(c)). To character-
ize CWEC proliferation, we performed immunohistochem-
ical staining for proliferating cell nuclear antigen (PCNA),
a nuclear protein expressed in G1-M phase [84], in SD and
PCK rat liver. In PCK rat liver, PCNA was strongly expressed
in CWECs compared to limited PCNA-positive staining
in cholangiocytes in SD rat liver (Figure 2(a)). Additional
studies suggest that pericystic fibrosis occurs in parallel with
biliary dysgenesis in PCK rats [29, 39]. By using picrosirius
red staining to localize ECM, we found an increased level
of fibrillar collagen deposition in PCK rat liver compared to
that observed in SD rats (Figure 2(b)). In addition to cyst
growth and pericystic fibrosis in PCK rat liver, we recently
measured hepaticMCP-1 transcript levels in SD and PCK rats
as a surrogate marker of hepatic inflammation and driver of
fibrosis. The expression of MCP-1 was elevated in PCK rat
liver compared to SD rats at PND 5, 10, 20, and 30, which is
consistent with the work showing that MCP-1 is upregulated
in PCK rat kidney [83]. While further studies are required,
these data suggest that increased inflammation, perhaps
mediated by macrophages or PFs, is a potent contributor to
CHF/ARPKD progression.
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Figure 1: Characterization of hepatic cyst growth in PCK rats. (a) Liver/body weight ratio (as a percent of body weight) in Sprague-Dawley
(SD) and polycystic kidney (PCK) rats was calculated from postnatal day (PND) 0 to PND 90. ∗, significantly different than SD rats at the
indicated time point (𝑝 < 0.05). (b) Cyst number was quantified in 200x, hematoxylin and eosin-stained images from PCK rats between
PND 0 and PND 90. ∗, significantly different than PND 0 (𝑝 < 0.05). (c) Pearson correlation of the relationship between liver weight and
cyst number in PCK rats from PND 0 to PND 90. In all cases, 𝑛 = 2–4 rats per genotype per time point.
8. (Pathogenic Triumvirate) in
CHF/ARPKD: Insights into the
Development of New Therapies
Althoughmutations in the human PKHD1 gene, ormutations
in PKHD1 orthologs in rats and mice, are required for
development of CHF/ARPKD, other factors are also involved
in disease progression. It is from a review of the published
literature summarized in this paper that we propose a
“pathogenic triumvirate” in CHF/ARPKD which includes
three factors, cyst growth, fibrosis, and inflammation, as
mediators which contribute to disease progression (Figure 3).


























































Figure 2: Cyst wall epithelial cell proliferation, fibrosis, and inflammation in PCK rats. (a) Hyperproliferation of cystic epithelia in polycystic
kidney (PCK) rats. Hepatic PCNA content was assessed in Sprague-Dawley (SD) rats and PCK rats by immunohistochemistry. Images were
taken at 400x magnification. Arrows indicate PCNA-positive cyst wall epithelial cells (CWECs) and asterisks indicate hepatic cysts. (b)
Pericystic fibrosis in PCK rats. Extracellular matrix was localized in livers from SD and PCK rats by picrosirius red staining. Images were
taken at 100x magnification. A scale bar (100 𝜇M) is included in each image. PV = portal vein, CV = central vein, and asterisks = cysts (some,
but not all are indicated). (c) Inflammation in PCK rats. Monocyte chemoattractant protein-1 (MCP-1) transcripts in SD (blue circles) and
PCK (red squares) rats frompostnatal days (PND) 0 to 90weremeasured in liver using real-time PCR as a surrogatemarker for inflammation.
The data are expressed as fold change over control (SD) at PND 0. All images are representative of 𝑛 = 2–4 rats at each time point and data
are graphed as means plus standard error of the mean. ∗𝑝 < 0.05 between SD and PCK rats at the time points indicated.
Despite recent advances in our understanding of what con-
tributes to the pathology of CHF/ARPKD, less is known
about themolecularmechanisms regulating cyst growth, pro-
gression of fibrosis, and how inflammation contributes to
these interrelated processes. Furthermore, whether or not a
common mechanism drives members of the “pathogenic tri-
umvirate” is also not known. We propose that leveraging
what we do know about the CHF/ARPKD pathogenesis in
the context of the pathogenic triumvirate will lead the way to
new research and, possibly, new therapies for this disease. For
example, finding a central mechanism that regulates all three
components would be an attractive target for the develop-
ment of new pharmacologic approaches to manage CHF/
ARPKD. Alternatively, if a common mechanism does not
exist, therapeutically targeting each member of the triumvi-
rate concurrently may be a favorable approach.
9. Summary and Conclusions
CHF/ARPKD is a genetic disease, but many factors con-
tribute to its pathology and progression. Cyst growth is
mainly regulated by cAMP and intracellular [Ca2+] through
stimulating cholangiocyte proliferation and fluid secretion.
While these signals are clearly important in CHF/ARPKD,
additionalmolecules and pathways which drive cell prolifera-
tion in cystic disease are being discovered and require further
exploration. Development of hepatic fibrosis depends on
the balance between ECM synthesis and degradation. Much
research is needed not only to understand the role of the
ECM in disease progression but also to define which cells are
responsible for development of fibrosis in the first place (e.g.,
HSCs, PFs). Even less is known regarding the role inflam-
mation plays in CHF/ARPKD. Future research should focus
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Figure 3: A “pathogenic triumvirate” in congenital hepatic fibrosis
(CHF) in autosomal recessive polycystic kidney disease (ARPKD).
Published data suggest that cyst growth, fibrosis, and inflamma-
tion drive CHF/ARPKD (solid purple arrows). We propose that
relationships exist between cyst growth, fibrosis, and inflammation
which drive progression of CHF/ARPKD (black, double-headed
arrows with broken lines). Targeting a single pathway which drives
each of the triumvirate members, or targeting multiple members
concurrently, may provide better therapeutic strategies than if
targeting any one member in isolation.
on identifying immune cell types and inflammatory medi-
ators found in CHF/ARPKD and elucidating their roles in
protection or promotion of disease. To date, the treatments
for ARPKD are very limited and rely mostly on liver/kidney
transplantation. Our “pathogenic triumvirate” identifies
three target areas, cyst growth, fibrosis, and inflammation,
which influence CHF/ARPKD progression. We believe that
an integrated approach targeting each member of the patho-
genic triumvirate at the same time, either byway of a common
core pathway or three independent pathways, is required
to improve therapeutic strategies for CHF/ARPKD. Further
studies, utilizing the PCK rat or relevant mouse models of
CHF/ARPKD, should strive to implement this idea in the
preclinical arena.
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